Published in J Immunother on February 06, 2012
Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Sci Rep (2014) 0.93
Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy. Int J Mol Sci (2015) 0.88
Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity. Sci Rep (2016) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol (2009) 4.63
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol (2012) 3.34
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol (2012) 3.07
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 2.76
A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol (2011) 2.68
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. Eur Urol (2008) 2.66
Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. PLoS One (2013) 2.65
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol (2013) 2.43
Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol (2006) 2.24
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU Int (2010) 2.14
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol (2011) 2.11
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med (2007) 2.08
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol (2009) 2.02
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol (2007) 2.02
Exosomes as biomarker treasure chests for prostate cancer. Eur Urol (2010) 1.94
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol (2008) 1.94
IFNγ induces monopoiesis and inhibits neutrophil development during inflammation. Blood (2011) 1.88
Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood (2010) 1.86
Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res (2006) 1.83
A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet (2011) 1.78
Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res (2008) 1.68
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med (2010) 1.68
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol (2010) 1.66
Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. J Immunol (2007) 1.66
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer (2007) 1.64
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int (2012) 1.62
Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol (2010) 1.61
Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol (2008) 1.58
Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol (2007) 1.57
Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int (2009) 1.56
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol (2006) 1.54
Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol (2002) 1.54
A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. Eur Urol (2012) 1.52
Anxiety and distress during active surveillance for early prostate cancer. Cancer (2009) 1.49
Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int (2009) 1.46
hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol (2007) 1.45
Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol (2008) 1.43
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer (2009) 1.41
A nonredundant role for plasmacytoid dendritic cells in host defense against the human fungal pathogen Aspergillus fumigatus. Cell Host Microbe (2011) 1.41
CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest (2011) 1.39
Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. J Immunol (2009) 1.39
The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol (2007) 1.39
Natural killer T cells in adipose tissue prevent insulin resistance. J Clin Invest (2012) 1.34
Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. J Immunol (2008) 1.33
Lipocalin 2 deactivates macrophages and worsens pneumococcal pneumonia outcomes. J Clin Invest (2013) 1.32
Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol (2011) 1.29
Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol (2004) 1.28
Towards an optimal interval for prostate cancer screening. Eur Urol (2011) 1.27
Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation (2003) 1.26
Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney Int (2005) 1.24
Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. Proc Natl Acad Sci U S A (2009) 1.23
Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. Blood (2008) 1.22
Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J Pathol (2005) 1.22
Discrimination between nontumor bladder tissue and tumor by Raman spectroscopy. Anal Chem (2006) 1.22
The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS One (2008) 1.18
Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res (2010) 1.17
An anti-inflammatory role for plasmacytoid dendritic cells in allergic airway inflammation. J Immunol (2009) 1.17
Chronic helminth infection promotes immune regulation in vivo through dominance of CD11cloCD103- dendritic cells. J Immunol (2011) 1.16
Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol (2011) 1.16
Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer (2014) 1.16
Schistosomes induce regulatory features in human and mouse CD1d(hi) B cells: inhibition of allergic inflammation by IL-10 and regulatory T cells. PLoS One (2012) 1.15
GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo. J Immunol (2009) 1.15
Lack of CD200 enhances pathological T cell responses during influenza infection. J Immunol (2009) 1.11
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol (2009) 1.09
Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. Circ Res (2011) 1.08
Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res (2011) 1.08
Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol (2008) 1.08
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol (2010) 1.07
CD4(+) T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease. J Clin Invest (2012) 1.07
Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS One (2012) 1.05
CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. Arterioscler Thromb Vasc Biol (2011) 1.05
Apical CD36 immunolocalization in human and porcine taste buds from circumvallate and foliate papillae. Acta Histochem (2010) 1.05
Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur Urol (2009) 1.05
Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J Nutr (2006) 1.04
High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat Commun (2013) 1.03
Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J Endocrinol (2007) 1.03
Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res (2011) 1.03
The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol (2011) 1.03
Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother (2004) 1.03
Both conventional and interferon killer dendritic cells have antigen-presenting capacity during influenza virus infection. PLoS One (2009) 1.02
Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol (2011) 1.02
Hyaluronan is apically secreted and expressed by proliferating or regenerating renal tubular cells. Kidney Int (2005) 1.00
Coculture of human liver macrophages and cholangiocytes leads to CD40-dependent apoptosis and cytokine secretion. Hepatology (2008) 1.00
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol (2012) 1.00
The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol (2009) 1.00
A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int (2011) 1.00
Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol (2009) 1.00
Cutting edge: pulmonary Legionella pneumophila is controlled by plasmacytoid dendritic cells but not type I IFN. J Immunol (2010) 1.00